Related Experiment Video
Updated: Jul 6, 2026
11:25
Busulfan as a Myelosuppressive Agent for Generating Stable High-level Bone Marrow Chimerism in Mice
Published on: April 1, 2015
Altered gene expression in busulfan-resistant human myeloid leukemia
Benigno C Valdez1, David Murray, Latha Ramdas
1Department of Stem Cell Transplantation and Cellular Therapy, University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, United States.
Leukemia Research
|March 15, 2008
Summary
Busulfan resistance in leukemia hinders stem cell transplants. Gene expression analysis revealed key cellular factors, including HSP90 and STAT3, that contribute to this resistance, offering potential therapeutic targets.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Busulfan (Bu) resistance is a significant challenge in hematopoietic stem cell transplantation (HSCT) for leukemia patients.
- Understanding the molecular mechanisms of Bu resistance is crucial for improving treatment outcomes.
Purpose of the Study:
- To identify cellular factors contributing to busulfan resistance in leukemia.
- To investigate the role of gene expression alterations in Bu resistance.
Main Methods:
- Established and characterized busulfan-resistant leukemia cell lines (CML and AML).
- Performed gene expression analysis to identify differentially expressed genes.
- Investigated the involvement of apoptosis pathways, caspases, HSP90, and STAT3.
Main Results:
- Resistant cell lines showed altered regulation of cell cycle proteins (CHK2, CDC2) and apoptosis-related genes.
- Busulfan-induced apoptosis was partially mediated by caspases.
- Up-regulation of HSP90 and activation of STAT3 were associated with Bu resistance.
- Inhibition of HSP90 sensitized resistant cells to busulfan.
- Patient-derived cells showed similar gene expression patterns, validating the in vitro model.
Conclusions:
- Busulfan resistance in leukemia involves complex molecular alterations, including dysregulation of apoptosis and activation of HSP90/STAT3 pathways.
- The developed in vitro model accurately reflects clinical busulfan resistance.
- Targeting HSP90 and STAT3 pathways may represent a novel therapeutic strategy to overcome busulfan resistance in leukemia.
